VVYA Stock Overview
A clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.26 |
| 52 Week High | €7.66 |
| 52 Week Low | €7.59 |
| Beta | 1.88 |
| 11 Month Change | 0% |
| 3 Month Change | 0.33% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -62.56% |
| Change since IPO | -57.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| VVYA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -0.4% |
| 1Y | n/a | -21.1% | 5.6% |
Return vs Industry: Insufficient data to determine how VVYA performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how VVYA performed against the UK Market.
Price Volatility
| VVYA volatility | |
|---|---|
| VVYA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: VVYA's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine VVYA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Frank Weber | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Fundamentals Summary
| VVYA fundamental statistics | |
|---|---|
| Market cap | €62.04m |
| Earnings (TTM) | -€31.18m |
| Revenue (TTM) | n/a |
-17.1x
P/S Ratio-2.0x
P/E RatioIs VVYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVYA income statement (TTM) | |
|---|---|
| Revenue | -€3.62m |
| Cost of Revenue | -€525.00k |
| Gross Profit | -€3.09m |
| Other Expenses | €28.09m |
| Earnings | -€31.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | 85.50% |
| Net Profit Margin | 861.46% |
| Debt/Equity Ratio | 0% |
How did VVYA perform over the long term?
See historical performance and comparison